Klotho Neurosciences (KLTO) Competitors $0.92 -0.04 (-4.55%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock KLTO vs. ENGN, LIMN, ENTA, SLS, ACRS, KYTX, LFVN, CTOR, ALEC, and BIOAShould you be buying Klotho Neurosciences stock or one of its competitors? The main competitors of Klotho Neurosciences include enGene (ENGN), Liminatus Pharma (LIMN), Enanta Pharmaceuticals (ENTA), SELLAS Life Sciences Group (SLS), Aclaris Therapeutics (ACRS), Kyverna Therapeutics (KYTX), Lifevantage (LFVN), Citius Oncology (CTOR), Alector (ALEC), and BioAge Labs (BIOA). These companies are all part of the "pharmaceutical products" industry. Klotho Neurosciences vs. Its Competitors enGene Liminatus Pharma Enanta Pharmaceuticals SELLAS Life Sciences Group Aclaris Therapeutics Kyverna Therapeutics Lifevantage Citius Oncology Alector BioAge Labs Klotho Neurosciences (NASDAQ:KLTO) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Do insiders and institutionals have more ownership in KLTO or ENGN? 20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 26.7% of Klotho Neurosciences shares are held by company insiders. Comparatively, 10.4% of enGene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is KLTO or ENGN more profitable? enGene's return on equity of -32.60% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Klotho NeurosciencesN/A -1,779.01% -275.01% enGene N/A -32.60%-28.26% Do analysts rate KLTO or ENGN? enGene has a consensus target price of $23.29, suggesting a potential upside of 507.98%. Given enGene's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Klotho Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, KLTO or ENGN? Klotho Neurosciences is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKlotho NeurosciencesN/AN/A-$6.15M-$0.36-2.56enGeneN/AN/A-$55.14M-$1.65-2.32 Does the media favor KLTO or ENGN? In the previous week, enGene had 15 more articles in the media than Klotho Neurosciences. MarketBeat recorded 15 mentions for enGene and 0 mentions for Klotho Neurosciences. enGene's average media sentiment score of 0.05 beat Klotho Neurosciences' score of 0.00 indicating that enGene is being referred to more favorably in the news media. Company Overall Sentiment Klotho Neurosciences Neutral enGene Neutral Which has more volatility and risk, KLTO or ENGN? Klotho Neurosciences has a beta of 10.92, meaning that its stock price is 992% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.41, meaning that its stock price is 141% less volatile than the S&P 500. SummaryenGene beats Klotho Neurosciences on 10 of the 14 factors compared between the two stocks. Get Klotho Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLTO vs. The Competition Export to ExcelMetricKlotho NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.39M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-2.568.9728.7823.81Price / SalesN/A437.65372.2066.04Price / CashN/A157.7635.4557.96Price / Book23.004.838.275.54Net Income-$6.15M$31.62M$3.25B$259.28M7 Day Performance-25.21%-5.28%-3.70%-4.64%1 Month Performance-22.70%4.38%4.34%4.41%1 Year PerformanceN/A-2.49%25.90%17.95% Klotho Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLTOKlotho NeurosciencesN/A$0.92-4.6%N/AN/A$44.39MN/A-2.56N/AGap DownENGNenGene3.4666 of 5 stars$3.45-5.2%$23.29+574.9%-56.5%$176.30MN/A-2.0931LIMNLiminatus PharmaN/A$6.69-17.2%N/AN/A$174.01MN/A0.00N/ANews CoverageAnalyst DowngradeGap DownENTAEnanta Pharmaceuticals3.7048 of 5 stars$8.10+0.9%$18.50+128.4%-52.0%$173.18M$67.64M-1.78160News CoverageUpcoming EarningsAnalyst RevisionGap UpSLSSELLAS Life Sciences Group2.3322 of 5 stars$1.69-5.1%$7.00+314.2%+34.4%$168.62MN/A-4.4510News CoveragePositive NewsOptions VolumeACRSAclaris Therapeutics2.0161 of 5 stars$1.55-7.7%$8.71+462.2%+15.9%$167.83M$18.72M-1.12100News CoverageUpcoming EarningsAnalyst RevisionHigh Trading VolumeKYTXKyverna Therapeutics2.877 of 5 stars$3.85-11.1%$18.50+380.5%-56.2%$166.39MN/A-1.1496LFVNLifevantage3.8043 of 5 stars$12.91-1.7%$30.50+136.3%+55.9%$162.54M$200.16M18.71260CTORCitius Oncology1.3467 of 5 stars$2.06+10.2%$3.00+45.6%N/A$161.44MN/A0.00N/AALECAlector4.033 of 5 stars$1.61-8.5%$4.17+158.8%-74.7%$160.99M$88.34M-1.28270News CoverageUpcoming EarningsBIOABioAge LabsN/A$4.48-1.1%N/AN/A$160.61MN/A0.00N/APositive News Related Companies and Tools Related Companies enGene Competitors Liminatus Pharma Competitors Enanta Pharmaceuticals Competitors SELLAS Life Sciences Group Competitors Aclaris Therapeutics Competitors Kyverna Therapeutics Competitors Lifevantage Competitors Citius Oncology Competitors Alector Competitors BioAge Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLTO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
